Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial

MenACYW-TT (MenQuadfi®) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for use in individuals ≥12 months. This study assessed whether serogroup C immune responses with MenACYW-TT were at least non-inferior, or superior, to those of quadrivalent meningococcal ACWY...

Full description

Bibliographic Details
Main Authors: Markus Knuf, Mika Rämet, Nina Breinholt Stærke, Isabelle Bertrand-Gerentes, Yaël Thollot, Siham B'Chir, Habiba Arroum, Philipp Oster
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
menacyw-tt
menc-tt
mcv4-tt
immunogenicity
invasive meningococcal disease
meningococcal serogroup c
seroprotection
superiority
non-inferiority
toddlers
Online Access:http://dx.doi.org/10.1080/21645515.2022.2052657

Internet

http://dx.doi.org/10.1080/21645515.2022.2052657

Similar Items